We recently compiled a list of the Jim Cramer’s Game Plan for This Week: 8 Stocks in Focus. In this article, we are going to take a look at where Carnival Corporation & plc (NYSE:CCL) stands against the other stocks featured in Jim Cramer’s game plan. Jim Cramer, host of Mad Money, provided insights on Friday […]

It's not uncommon for rivalries to exist within family dynamics. Some of the most intense family rivalries involve family members competing on opposite teams in the same sport or working for different companies in the same sector. However, family ...

NEW YORK, December 17, 2024--Wise has been selected to facilitate Morgan Stanley’s foreign exchange international settlement capabilities for corporate customers.

MicroStrategy, the largest Bitcoin hoarder, will join the Nasdaq-100 on Dec. 23, leaving a far-reaching effect on itself, bitcoin, and the Nasdaq-100 index and ETFs.

LONG BEACH, Calif., December 17, 2024--Rocket Lab has successfully delivered its second Pioneer spacecraft to Vandenberg Space Force Base and completed production of a third for Varda.

Investment management company Ave Maria recently released its “Ave Maria Value Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund returned 10.12% compared to 6.94% return for the S&P Mid Cap 400 Index and 5.89% for the S&P 500 Index. You can check […]

We recently compiled a list of the Jim Cramer’s Game Plan for This Week: 8 Stocks in Focus. In this article, we are going to take a look at where General Mills, Inc. (NYSE:GIS) stands against the other stocks featured in Jim Cramer’s game plan. Jim Cramer, host of Mad Money, provided insights on Friday about […]

Teva hosting investor call today at 8:00 a.m. ET (U.S.)Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of T

SEALSQ Corp ( (LAES) ) just unveiled an update. SEALSQ Corp is undertaking an offering of 7,692,308 ordinary shares, facilitated through a Registration Statement filed with the U.S. Securities and Exchange Commission. This legal opinion from Harney Westwood & Riegels confirms that the issuance of these shares has been duly authorized under British Virgin Islands law, ensuring they will be validly issued, fully paid, and non-assessable once allocated. This development is pivotal for SEALSQ Corp a

The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.